Welcome to our dedicated page for OrthoPediatrics news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on OrthoPediatrics stock.
OrthoPediatrics Corp. (symbol: KIDS) is a global leader in pediatric orthopedics, exclusively focusing on providing innovative solutions for children with orthopedic conditions and injuries. The company is dedicated to advancing pediatric orthopedics by developing state-of-the-art technologies, ensuring high-quality products, and offering unparalleled support and clinical education through its team of experts.
OrthoPediatrics offers a wide range of anatomically appropriate implants and instruments designed to meet the unique needs of pediatric orthopedic surgeons. Their product portfolio includes solutions for long bone deformity correction and trauma, spine, and sports medicine. Among their flagship products are PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and the ACL Reconstruction System.
Recent achievements of OrthoPediatrics include issuing the 2024 financial guidance and recording a full-year revenue of $148.7 million in 2023, marking a 22% increase compared to the previous year. As of December 31, 2023, the company had cash and cash equivalents, short-term investments, and restricted cash totaling $82.3 million. The recent acquisition of Boston Orthotics & Prosthetics was a significant milestone, further reinforcing their market position.
In the first quarter of 2024, OrthoPediatrics reported a 41% increase in revenue year-over-year. The company's total other expense was $0.6 million for the quarter, primarily due to a favorable fair value adjustment in the previous year that did not recur in 2024, as well as additional interest expenses related to a new term loan with MidCap. As of March 31, 2024, the company's cash, cash equivalents, short-term investments, and restricted cash were $49.7 million.
OrthoPediatrics continues to seek talented professionals to join their mission. Interested candidates can visit their website to learn about current openings or submit their resumes to careers@orthopediatrics.com. For the latest updates, news, and developments, shareholders and potential investors can find the most recent information on OrthoPediatrics Corp. through this page.
OrthoPediatrics Corp. (KIDS) announced the launch of its RESPONSE 5.5/6.0 Cannulated Screw System, enhancing its RESPONSE™ Scoliosis portfolio. This marks the company's 47th surgical system, reinforcing its commitment to pediatric orthopedic innovation. The system features instruments and implants designed to improve screw placement accuracy and efficiency in surgeries. Early feedback from surgeons has been overwhelmingly positive, highlighting the system's effectiveness for the S1AI screw placement technique. The new product reflects OrthoPediatrics' dedication to advancing pediatric orthopedic solutions and its global reach in serving over 70 countries.
OrthoPediatrics Corp. (NASDAQ: KIDS) announced the upcoming release of its first quarter 2023 financial results on May 1, 2023, after market close. A conference call will be held on May 2, 2023, at 8:00 a.m. ET to discuss these results. The company, founded in 2006, specializes in pediatric orthopedics and currently offers 47 surgical systems targeting trauma, deformity, scoliosis, and sports medicine. OrthoPediatrics operates globally, distributing its products in the U.S. and over 70 additional countries. Investors can access the conference call via a live and archived webcast on the company's website.
OrthoPediatrics Corp. (Nasdaq: KIDS) will have its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 8:45 am ET. This event highlights the company's dedication to pediatric orthopedics, having developed the most comprehensive product offerings in this field. Founded in 2006, OrthoPediatrics markets 47 surgical systems across trauma, scoliosis, and sports medicine, serving the U.S. and over 70 countries globally. An audio webcast will be available at their investor relations site, with a replay following the event.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its sponsorship at the European Pediatric Orthopaedic Society (EPOS) annual meeting in Krakow, Poland. The company showcased its commitment to pediatric orthopedics by hosting an exhibit and a surgeon luncheon focused on Osteogenesis Imperfecta, featuring insights from leading surgeons. This event fosters collaboration among orthopedic surgeons across Europe, enhancing educational opportunities in the field. Currently, OrthoPediatrics offers 47 surgical systems covering trauma, scoliosis, and sports medicine, distributing its products in the U.S. and over 70 countries worldwide.
OrthoPediatrics Corp. (Nasdaq: KIDS) has been recognized as one of the 2023 Best Places to Work in Indiana, marking the 7th time the company has received this honor. Due to the company's growth, it now qualifies in the 'Large Employer' category. CEO David Bailey expressed pride in the achievement, emphasizing the importance of employee feedback in fostering a positive workplace culture. The awards ceremony will occur on May 10, 2023, and the final rankings will be published in the Indiana Chamber’s BizVoice® magazine. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering 46 surgical systems worldwide.
OrthoPediatrics Corp. (KIDS) reported a 25% increase in fourth quarter 2022 revenue, reaching $31.0 million, and a record $122.3 million for the full year 2022, also a 25% rise from 2021. The company helped nearly 17,000 children in Q4 and approximately 70,000 children throughout the year. Domestic and international revenues rose by 19% and 47% respectively for the year. Adjusted EBITDA improved to a positive $0.2 million. For 2023, the company expects revenue to be between $146 million to $149 million, anticipating 20% to 22% growth compared to 2022.
OrthoPediatrics Corp. (NASDAQ: KIDS) announced it will release its Q4 and full year 2022 financial results on February 28, 2023, after market close. A conference call to discuss these results is scheduled for March 1, 2023, at 8:00 a.m. ET. The call can be accessed through a live and archived webcast on the company's website. OrthoPediatrics specializes in pediatric orthopedics, offering 46 surgical systems for trauma, scoliosis, and sports medicine, distributing its products in the U.S. and over 70 countries globally.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced preliminary unaudited net revenue for Q4 2022 at $31.0 million, a 25% increase from $24.8 million in Q4 2021. Full year 2022 net revenue is projected at $122.3 million, up 25% from $98.0 million in 2021. Domestic revenue grew 19% and international revenue increased by 47%. For 2023, the company forecasts net revenue between $146.0 million and $149.0 million, reflecting a growth of 20% to 22%. The report highlighted challenges due to surgery schedule disruptions in children's hospitals due to viral infections but emphasized a strong strategic position.
OrthoPediatrics Corp. (Nasdaq: KIDS) has launched a direct sales organization in Germany, commencing operations on January 1, 2023. This marks its first direct international presence, reflecting a commitment to enhance pediatric orthopedics globally. The new entity, OrthoPediatrics GmbH, aims to better address the unique needs of the German pediatric community, one of Europe’s largest orthopedic markets. The company will continue partnerships with local organizations to support pediatric orthopedic education. OrthoPediatrics offers a comprehensive range of products targeting trauma, deformity correction, and spinal issues.
FAQ
What is the current stock price of OrthoPediatrics (KIDS)?
What is the market cap of OrthoPediatrics (KIDS)?
What does OrthoPediatrics Corp. do?
What are some of OrthoPediatrics' key products?
What were OrthoPediatrics' financial highlights for 2023?
How did OrthoPediatrics perform in the first quarter of 2024?
What recent acquisition did OrthoPediatrics make?
How much cash and equivalents did OrthoPediatrics have as of March 31, 2024?
What is OrthoPediatrics' focus in pediatric orthopedics?
Where can I learn about career opportunities at OrthoPediatrics?
Who can I contact for investor relations at OrthoPediatrics?
What recent financial guidance did OrthoPediatrics issue?
